Polyendocrinopathy
MONDO:001512676 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo tested for tough breast cancer
Disease control CompletedThis study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The …
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Community strategies show promise in curbing hazardous drinking
Disease control CompletedThis study tests a 5-week community-based program that teaches protective behavioral strategies to reduce alcohol use in men aged 35–44 with hazardous drinking habits in rural Vietnam. Participants learn to set safe drinking limits, choose nonalcoholic drinks, and plan ahead, wit…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cholesterol-Lowering drug aims to stop first heart attacks
Disease control CompletedThis large study tested whether evolocumab (Repatha), a cholesterol-lowering injection, could reduce major cardiovascular events like heart attacks, strokes, or death in over 12,000 adults at high risk but without a prior heart attack or stroke. Participants received either evolo…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Pump delivery of hormone may steady calcium levels in rare disorder
Disease control CompletedThis study tested two ways of delivering synthetic parathyroid hormone (PTH) to people with chronic hypoparathyroidism, a condition where the body doesn't make enough PTH, causing low calcium. Researchers compared using an insulin pump to give steady, small doses versus twice-dai…
Phase: PHASE2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New male pill aims to stop sperm production
Disease control CompletedThis study tested whether a daily oral pill can safely and temporarily lower sperm counts in healthy men to prevent pregnancy. Ninety-two men took either the experimental drug (DMAU) alone, DMAU plus another hormone (LNG), or a placebo for 12 weeks. The goal was to see if sperm c…
Phase: PHASE2 • Sponsor: Premier Research • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Which dose of vandetanib works best for thyroid cancer?
Disease control CompletedThis study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill shows promise in slowing rare thyroid cancer
Disease control CompletedThis phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many pa…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Virtual fitness and nutrition program aims to keep older men on their feet
Prevention CompletedThis pilot study tested a virtual program designed to help older men at high risk for fractures reduce their risk of falls and broken bones. The program included personalized exercise plans delivered through a smartphone app and virtual nutrition counseling. Researchers enrolled …
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Your DNA may decide how well exercise and diet work for weight loss
Knowledge-focused CompletedThis study is testing whether a specific gene variant (MC4R rs17782313) and metabolic health status influence how men with obesity respond to a 12-week exercise and diet program. Forty men aged 18 to 59 with obesity will be classified as having metabolically healthy or unhealthy …
Phase: NA • Sponsor: Harbin Sport University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Protein shake vs. gut trouble: can whey help athletes digest fructose after heat stress?
Knowledge-focused CompletedThis pilot study tests whether a multi-ingredient whey supplement can reduce fructose malabsorption in healthy adults after hiking under heat stress. Eight participants will consume fructose and have their breath hydrogen measured as a marker of malabsorption, both before and aft…
Phase: NA • Sponsor: Arizona State University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Could a simple calculation replace a complex testosterone lab test?
Knowledge-focused CompletedThis study compared two methods for measuring bioavailable testosterone in the blood: the standard lab test (radioimmunoassay) and a mathematical calculation. Researchers included 270 men and women aged 18 to 90. The goal was to see if the calculation matches the lab test closely…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Men shape their own suicide prevention tools in new study
Knowledge-focused CompletedThis completed study brought together men who have had suicidal thoughts to help design suicide prevention tools. Over up to 10 meetings, 13 men gave feedback on tool drafts, focusing on usability, privacy, and support. The goal was to create resources that truly fit their needs.
Phase: NA • Sponsor: University Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Rare disease genetics unlocked: new study maps APECED mutations
Knowledge-focused CompletedThis study looked at the genetic makeup of 29 people with APECED syndrome, a rare autoimmune disorder. Researchers aimed to find common gene mutations and link them to symptoms. The goal was to better understand the disease and improve diagnosis.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC